MS one disease or should we suggest one syndrome or are we going to split it into smaller diseases based on different targets.

Antibody signatures in patients with histopathologically defined multiple sclerosis patterns. Stork L, Ellenberger D, Ruprecht K, Reindl M, Beißbarth T, Friede T, Kümpfel T, Gerdes LA, Gloth M, Liman T, Paul F, Brück W, Metz I. Acta Neuropathol. 2020 Jan 16. doi: 10.1007/s00401-019-02120-x. [Epub ahead of print] Early active multiple sclerosis (MS) lesions can be classified histologically into...

More evidence that B cells are driving relapse

Rebound of disease activity after fingolimod withdrawal: Immunological and gene expression profiling.Sacco R, Emming S, Gobbi C, Zecca C, Monticelli S.Mult Scler Relat Disord. 2020 Jan 3;40:101927 Abstract Discontinuation of disease-modifying therapy with fingolimod can lead to severe Multiple Sclerosis (MS) rebound activity; however, this phenomenon remains mechanistically incompletely...

The message is not getting heard, fingolimod works by inhibiting T cells. It’s behind you!!!

Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis. Ghadiri M, Rezk A, Li R, Evans A, Giacomini PS, Barnett MH, Antel J, Bar-Or A.Sci Rep. 2020 Jan 15;10(1):356 Biomarkers predicting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lacking. Here, we performed extensive functional immunophenotyping using...

Animals got it wrong again or is a fluke?

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental...

How Do you Want Your Information?

Hopefully you consider the Blog as a source of information, but how do you want that information delivered? Do you want it in a Faberge Egg or a paper bag? The paper bag costs $10 and the egg costs $5,000. Sure I know if it was a real Faberge egg it would be more, and $10 for a paper bag, you say I’m having a laugh, but the question I pose is a real question. I do work and I report it...

Interogating MS with new technology, it’s a T & B cell co-operation thang.

With new technology is was not a question of if, but a question of when the protein production array of individual cells will be done, You can now look for the antigen-specific receptors of each cell to find out what they target is you can look at the proteins they make to say what cell types are there and this latter aspect was the focus of this study. They got the protein signatures...

Newsflash: Avoid the Links from TRIMS.Online today

When is an International MS meeting a Shop front for Replacement Windows?


Don’t click on the links that are active if you view with a phone

You won’t get information for the meeting

Stay away from the links (above in italics) on your phone

Dear Oh Dear

Siponimod controls progressive MS by enhancing regulatory cells….It’s behind you!

As we are in pantomine season when the baddy (ghost) is behind you about to pounch, and when you ask I wonder where the baddy is? The audience shouts out “he’s behind you” and you don’t turn your head, you slowly turn your body as the baddy turns to stay behind your back, so when you turn round, there is nothing there. So you say “Oh no he isn’t” and the...

Anti-TNF therapy says MS is one disease

Since their introduction in 1999, anti-tumour necrosis factor-α (anti-TNF-α) therapies have been suspected repeatedly to be associated with the occurrence of central nervous system (CNS) demyelinating disorders, including multiple sclerosis (MS). However, recent publications were restricted to descriptions of monophasic demyelinating events or cases of relapsing-remitting MS (RRMS). We here...

Clinical trials vs. real-world data in MS

We probably don’t really require a study to tell us that those participating in clinical trials are not exactly the same as the general population that may take a particular treatment – we already know this. However, when it comes to MS drugs it is worth noting what the differences between the two populations are. According to Rojas et al., upon reviewing 18 clinical trials and 73...



Recent Posts

Recent Comments